Benitec Biopharma Inc. (BNTC): R&D Expense
$23.39M
Year ended 2026-06-30
+22.3%
3-year compound annual growth
+27.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $23.39M | +27.6% | 2026-09-14, From 2025-07-01 |
| 2025-06-30 | $18.33M | +17.4% | 2026-09-14, From 2024-07-01 |
| 2024-06-30 | $15.61M | +22.2% | 2026-03-20, From 2023-07-01 |
| 2023-06-30 | $12.77M | +13.3% | 2024-09-26, From 2022-07-01 |
| 2022-06-30 | $11.27M | +60.6% | 2023-09-21, From 2021-07-01 |
| 2021-06-30 | $7.02M | +133.9% | 2022-09-02, From 2020-07-01 |
| 2020-06-30 | $3.00M | -34.3% | 2021-09-20, From 2019-07-01 |
| 2019-06-30 | $4.57M | n/a | 2020-09-23, From 2018-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $23.39M | +27.6% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $45.62M | -2.9% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $61.12M | -27.7% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| PepGen Inc. (PEPG) | 2025-12-31 | $71.04M | -7.1% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $99.13M | -0.2% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $33.48M | -15.0% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $66.27M | +27.5% |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗